ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastasesTop-line pivotal data ...
Positive Outlook for ZEEKR: Buy Rating Amid Strategic Growth and Cost Efficiency
Morgan Stanley analyst Tim Hsiao maintained a Buy rating on ZEEKR Intelligent Technology Holding Limited Sponsored ADR (ZK – Research ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
In June, GSK released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial of Blenrep in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, ...
Fed's Kugler says Fed has made good progress on achieving mandates
NEW YORK (Reuters) - Federal Reserve governor Adriana Kugler said Thursday the central bank has made considerable progress in working to achieve its job and inflation goals, while stopping short of ...
Powell says no need for Fed to rush rate cuts given strong economy
But the pace of rate cuts "is not preset," Powell said at a Dallas Fed event, adding that "the economy is not sending any signals that we need to be in a hurry to lower rates. The strength we are ...
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
WASHINGTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious ...